Top Health Tools
Top Health Tools

Top Reports
Top Reports
 
Top Articles
Top Articles

Top Reviews
Top Reviews
   
FDA Approves Lethal Fluarix
Vaccine for Pediatric Use

The U.S. Food and Drug Administration approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated influenza A and B viruses, had been approved for use in adults, ages 18 years and older.

There are no long-term studies which establish the safety and effectiveness of Fluarix for use in children ages 3 years and older.

Fluarix is a seasonal influenza vaccine not intended to protect against the 2009 H1N1 influenza virus.

With this approval, there are now four companies approved by the FDA to manufacture seasonal influenza vaccine for use in children.

Influenza is more dangerous than the common cold for children, who sometimes require medical care, especially if they are younger than 5 years. Yet the FDA claims it is best to vaccinate children each and every fall with chemicals that GlaxoSmithKline lists as causing blood, lymphatic, cardiac, ear, eye, gastrointestinal, immune, nervous, respiratory, muscular, allergic and vascular disorders.

The above reactions are based on worldwide voluntary reports of adverse events received for Fluarix since market introduction of the vaccine. They do no include all reactions cause by the vaccine diagnosed by Physicians worldwide.

Fluarix is manufactured by GlaxoSmithKline Biologicals of Dresden, Germany.

Share/Bookmark
...............................................................................................................

This site is owned and operated by PreventDisease.com 1999-2014. All Rights Reserved. All content on this site may be copied, without permission, whether reproduced digitally or in print, provided copyright, reference and source information are intact and use is strictly for not-for-profit purposes. Please review our copyright policy for full details.
aaa
Interact
volunteerDonateWrite For Us
Stay Connected With Our Newsletter